Favipiravir
Favipiravir, also known as T-705, Avigan, or favilavir is an antiviral drug being developed by Toyama Chemical (Fujifilm group) of Japan with activity against many RNA viruses. In February 2020 Favipiravir was being studied in China for experimental treatment of the emergent COVID-19 (novel coronavirus) disease.[1][2] On March 17 it was found to be effective in treating the infection in two trials in Wuhan and Shenzhen.[3][4] Like certain other experimental antiviral drugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative. Favipiravir is also active against influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses.[5] Activity against enteroviruses[6] and Rift Valley fever virus has also been demonstrated.[7] Favipiravir has showed limited efficacy against Zika virus in animal studies, but was less effective than other antivirals such as MK-608.[8] The agent has also shown some efficacy against rabies,[9] and has been used experimentally in some humans infected with the virus.[10]
The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase.[11] Other research suggests that favipiravir induces lethal RNA transversion mutations, producing a nonviable viral phenotype.[12] Favipiravir is a prodrug that is metabolized to its active form, favipiravir-ribofuranosyl-5'-triphosphate (favipiravir-RTP), available in both oral and intravenous formulations.[13][14] Human hypoxanthine guanine phosphoribosyltransferase (HGPRT) is believed to play a key role in this activation process.[15] Favipiravir does not inhibit RNA or DNA synthesis in mammalian cells and is not toxic to them.[5] In 2014, favipiravir was approved in Japan for stockpiling against influenza pandemics.[16] However, favipiravir has not been shown to be effective in primary human airway cells, casting doubt on its efficacy in influenza treatment
Ebola virus disease
The drug appears to be effective in a mouse model of Ebola virus disease, but its efficacy against human Ebola infection is unproven.[18][19][20] During the 2014 West Africa Ebola virus outbreak, it was reported that a French nurse who contracted Ebola while volunteering for MSF in Liberia recovered after receiving a course of favipiravir.[21] A clinical trial investigating the use of favipiravir against Ebola virus disease was started in Guéckédou, Guinea, during December 2014.[22] Preliminary results showed a decrease in mortality rate in patients with low-to-moderate levels of Ebola virus in the blood, but no effect on patients with high levels of the virus, a group at a higher risk of death.[23] The trial design has been criticised by Scott Hammer and others for using only historical controls.[24] The results of this clinical trial were presented in February 2016 at the annual Conference on Retroviruses and Opportunistic Infections (CROI) by Daouda Sissoko[25] and published on March 1, 2016 in PLOS Medicine.[26]
SARS-CoV-2 virus disease
Early reports suggest the drug is effective in treating the disease.
ليست هناك تعليقات:
إرسال تعليق